> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CDER Sampling/Testing Program Explained
- URL: https://www.fdaweb.com/cder-sampling-testing-program-explained/
- Published: 2022-07-20T12:00:00.000Z
- Updated: 2026-09-14T17:52:39.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5152322

CDER Office of Quality Surveillance director **Jennifer Maguire** says FDA samples drugs for general quality surveillance and for targeted investigations in response to information about suspected quality issues with drugs on the market. In an online interview [post](https://www.fda.gov/drugs/news-events-human-drugs/cder-conversation-cders-drug-quality-sampling-and-testing-program?ref=fdaweb.com), Maguire says the information analyzed through the drug quality sampling and testing program “can be used to understand the state of quality for particular products, identify defective or potentially harmful products, and provide evidence for compliance actions.”

The post explains how the agency decides which drugs to test, what CDER does with the testing results, and what patients and consumers can do if they are concerned about the quality of a drug.